New Treatment Strategy Allows Lower Doses of Toxic Tuberculosis Drug Without Compromising Potency - 12/30/14

Already known to cut proteins, the enzyme SPPL3 turns out to have additional talents, according to a new study from Johns Hopkins. In its newly discovered role, SPPL3 works without cutting proteins to activate T cells, the immune system’s foot soldiers.